Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
PHARMACEUTICAL FORMULATIONS OF HER2 ANTIBODY-DRUG CONJUGATE
FIELD
100011 The present invention relates to a pharmaceutical formulation of Her2
antibody-drug
conjugate, which belongs to the field of antitumor drugs.
[0002]
BACKGROUND
100011 Tumor-targeted biotherapy has attracted more and more attention in the
research of
cancer treatment. Among them, monoclonal antibody therapy has a high
specificity against the
target and low side effects, but has a relatively limited efficacy when used
alone. Currently, the
most successfully anti-tumor monoclonal antibody drugs are those targeting
lymphocytic tumors,
such as non-Hodgkin's lymphoma (NEIL), chronic lymphocytic leukemia (CLL) and
so on.
100021 ErbB2, also known as Her2/neu, is the second member of the EGFR family,
which plays
a biological role by forming a heterodimer with the other three members of the
EGFR family. The
neu gene encoding ErbB2 was first isolated from rat neuroblastoma. The
homologous gene of the
neu gene in human somatic cells, called Her2, is located on the long arm of
chromosome 17
(17q21.1). ErbB2, the product encoded by Her2, consists of 1255 amino acids
and has a
molecular weight of about 185 kDa, in which positions 720-987 is the tyrosine
kinase active
domain. In addition to acting through the PI3K and MAPK signaling pathways,
ErbB2 can reduce
the expression of cyclin D and c-myc, thereby reducing the expression of
cyclin-dependent kinase
(CDK) inhibitor p27kip1. The activity of CDK2 is inhibited, leading to cell
proliferation. With the
continuous and in-depth research, it has been found that HER2 is expressed and
overexpressed in
a variety of tumors. Therefore, there is an urgent need for drugs targeting
HER2 to effectively
treat malignant tumors. There are currently three monoclonal antibodies
targeting Her2 on the
market (see Table 1).
[0003] Table 1 FDA approved monoclonal antibody drugs targeting Her2
Trade Name Common Name Company Target Indication FDA
Approved Date
- -
Date Recue/Date Received 2020-09-22
Herceptin Trastuzumab Roche Her-2 Breast Cancer 1998
Pen j eta Pe rtuzumab Genentech Her-2
Breast Cancer 2012
Mylan and Breast Cancer,
ogivri trastuzumab-dkst Biocon Her-2 Metastatic 2017
company Gastric Cancer
[0004] Based on the characteristics of antibody targeting, a new generation of
biological
targeting drugs, antibody-drug conjugate (ADC), has emerged. ADC consists of
three parts:
antibody, cytotoxin, and a linker connecting the two together. After
conjugating the monoclonal
antibody to the cytotoxin, the antibody-drug conjugate utilizes the targeting
of the monoclonal
antibody to specifically recognize the receptor on the surface of the cancer
cell, binds to the
receptor, and then enters the cell, and releases a cytotoxic substance via the
intracellular protease
to stop cancer cells from reproducing and kill them. In the prior art,
mammalian cell culture is
generally used to produce an antibody, and the highly purified antibody is
conjugated to the
cytotoxin such as MMAE via a linker to obtain the antibody-drug conjugate
(ADC). Antibody
drug conjugating technology integrates a small molecule toxin drug and a
biological protein, so
that it owns the advantages of both, becoming a new generation of therapeutic
product, which
greatly enhances the efficacy of the drug while reducing toxic and side
effects. Currently, there
are four ADCs drugs on the market approved by the US FDA (see Table 2).
Table 2 Four ADC drugs on the market
FDA
Approved
Trade Name Common Name Company Target Indication Date
Gemtuzumab Acute Skeletal
Mylotarg Pfizer CD33
2000/2017
Ozogamicin Leukemia
- 2 -
Date Recue/Date Received 2020-09-22
Hodgkin lymphoma,
Brentuximab Seattle
Adcetris CD30 Anaplastic Large Cell
2011
Vedotin Genetics
Lymphoma
Ado-Trastuzumab
Kadcyla Roche Her-2 Breast Cancer 2013
Emtansine
Ino tuzumab Acute Lymphoblastic
Besponsa Pfizer CD22 2017
Ozogamicin Leukemia
[0005] Like other biomacromolecule drugs, ADCs are prone to degradation such
as oxidation,
deamidation and fragmentation, or forming microparticles and aggregates. In
addition,
conjugation itself may reduce the stability and change the physicochemical
properties of the
antibody. For example, the conjugating of DM1 to the anti-HER2 antibody
trastuzumab results in
the loss of stability of the CH2 domain of the antibody (Reference 1:
Physicochemical Stability of
the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and
Conjugation
Processes. Aditya A. Wakankar et al., Bioconjugate Chemistry 2010: 21(9), 1588-
1595). ADC
drug is generally hydrophobic and as a whole may be more insoluble than an
unconjugated
antibody, and therefore become more prone to aggregation, forming
microparticles or surface
adsorption. In order to provide ADC drugs that are stable during
transportation and storage, each
adjuvant ingredient in the pharmaceutical formulation must be carefully
selected. The adjuvant
ingredients of ADCs currently on the market are as shown in Table 3. Since the
types of adjuvant
ingredient used in the ADC formulation currently on the market are very
limited and there are
many choices of the related ingredient of the formulation, the development of
an adjuvant
combination for the ADC formulation that are stable during transportation and
storage involves
the screening of a large number of adjuvant ingredients, also, the
determination of the appropriate
concentration requires a lot of effort and time.
Table 3 Adjuvant ingredients of ADCs on the market
Trade Name Common Name Adjuvant Ingredient
- 3 -
Date Recue/Date Received 2020-09-22
Dextran 40
Sucrose
Gemtuzumab
Mylotarg Sodium chloride
Ozogamicin
Monobasic sodium phosphate monohydrate
Dibasic sodium phosphate anhydrous
Citric acid monohydrate
Brentuximab Sodium citrate dihydrate
Adcetris
Vedotin a, a-Trehalose dihydrate
Polysorbate 80
Sucrose
Ado-Trastuzumab Succinic Acid
Kadcyla
Emtansine Polysorbate20
Sodium hydroxide
Sucrose
Ino tuzumab Polysorbate 80
Besponsa
Ozogamicin Sodium chloride
Tromethamine
100061 It can also be seen from the adjuvant ingredients of the above four ADC
formulations
that each formulation is unique in the adjuvant ingredients used. Due to the
low stability and
complicated structure of monoclonal antibody drugs, it is extremely
challenging to manufacture
and store such drugs. Due to the heterogeneous structure of antibodies, in
particular the
complementarity determining regions (CDRs) and Fc glycosylation, the
development of different
monoclonal antibody formulations needs to be carried out individually based on
case (Reference
2: Monoclonal antibodies: formulations of marketed products and recent
advances in novel
delivery system, Yanan Cui et al., Drug Development and Industrial Pharmacy,
Volume 43, No. 4,
Pages 519-530, 2017). In addition, the development of formulations for ADCs
are more unique
because the further involvement of conjugation and a toxin molecule.
[0007] The patent application (CN105008398A or W02015074528A1) discloses a
humanized
RC48 antibody-drug conjugate, wherein the humanized RC48 antibody is a
monoclonal antibody
targeting Her2 (an antibody secreted from the hamster ovary cells (CHO cells)
which were
deposited at the China Center for Type Culture Collection with the deposit
number of C2013170
or an antibody derived therefrom), and the cytotoxin is Monomethyl Auristatin
E (MMAE),
which is a derivative of dolastatin. The linker in this ADC is
- 4 -
Date Recue/Date Received 2020-09-22
Maleimido-Caproyl-Valine-Citrulline-p-AminoBenzyloxy (mc-VC-PAB), and the
recombinant
humanized Her2 monoclonal antibody-MMAE conjugate is formed by the monoclonal
antibody
and MMAE linked to the linker through cysteine. The drug has achieved good
therapeutic effects
in Her2 positive tumor.
100081 The preliminary experiments showed that, after purification, the
recombinant
humanized anti-Her2 monoclonal antibody-MMAE conjugate has a poor solubility
in the
conventional buffer, and visible insoluble microparticles will appear, which
does not meet the
standards for injection. However, if a clinically effective therapeutic dose
is to be achieved, the
protein concentration needs to be above 5 mg/ml. Therefore, there is a need to
solve the problem
of insoluble particles while ensuring a certain effective concentration. In
addition, when the
protein solution is lyophilized under vacuum, it is necessary to add a
lyoprotectant to protect the
protein from being destroyed during lyophilization, and to ensure that the
lyophilized powder has
a good appearance at the same time. In order to avoid the slow degradation of
lyophilized powder
of the protein during long-term storage, it is necessary to add an appropriate
protein stabilizer.
Lots of experiments are needed to develop and determine the appropriate
protein stabilizer.
[0009] Therefore, the purpose of the present invention is to develop a
combination of adjuvants
for anti-Her2 monoclonal antibody-MMAE conjugate through a wide range
screening and
concentration range screening to achieve the following technical effects: the
anti-Her2
monoclonal antibody-MMAE conjugate can dissolve well before and after
lyophilization, and
both the insoluble microparticles and the visible precipitates meet the
standards for human
injection; in addition, the conjugate can be stable for a long time during
lyophilization and
storage, not be easily polymerized or degraded after reconstitution, and still
maintains good
biological activity.
SUMMARY
100101 The present invention provides an aqueous liquid pharmaceutical
formulation of an
antibody-drug conjugate, wherein the formulation comprises the antibody-drug
conjugate, a
non-reducing sugar, an amino acid, and a solubilizer; wherein the non-reducing
sugar is selected
from mannitol, sucrose, trehalose, and a combination thereof; the amino acid
is selected from
- 5 -
Date Recue/Date Received 2020-09-22
histidine, alanine, arginine, glycine, glutamic acid, and a combination
thereof; and the solubilizer
is selected from glycerol, Tween 80, and a combination thereof.
[0011] In some embodiments, the concentration of the mannitol is 100-300
mmol/L, preferably
190-300 mmol/L, more preferably 200-260 mmol/L, most preferably 240-260
mmol/L. The
.. concentration of the sucrose is 0-100 mmol/L, preferably 40-100 mmol/L,
more preferably
60-100 mmol/L, most preferably 40-60 mmol/L.
[0012] In some embodiments, the histidine is histidine hydrochloride at a
concentration of
0-100 mmol/L, preferably 5-50 mmol/L, more preferably 5-20 mmol/L, most
preferably 10
mmol/L. The arginine is arginine hydrochloride at a concentration of 0-160
mmol/L, preferably
20-100 mmol/L, more preferably 30-90 mmol/L, most preferably about 35 mmol/L.
[0013] In some embodiments, the content of the glycerol is 0-1%, preferably
0.2-0.5% (w/v).
The mass percentage of Tween 80 is 0-0.02% (w/v).
[0014] Further, the antibody in the antibody-drug conjugate is an anti-HER2
monoclonal
antibody; and the drug to which the antibody is conjugated is MMAE, MMAF, DM1,
DM4, or a
derivative thereof.
[0015] Further, the anti-HER2 antibody-drug conjugate is an anti-HER2
monoclonal
,111 1 le õ
antibody-vc-MMAE, wherein the anti-HER2 monoclonal antibody is connected to
MMAE via a
linker vc, and the structure formed by the connection of the linker and MMAE
is:
111 II
12; 41 1 A-
1:1A4
=
100161 Further, the anti-HER2 monoclonal antibody comprises a heavy chain and
a light chain,
(i) the heavy chain comprises CDRs 1-3 having amino acid sequences shown in
SEQ ID NO:
1, 2 and 3, respectively; and/or
(ii) the light chain comprises CDRs 1-3 having amino acid sequences shown in
SEQ ID NO:
4, 5 and 6, respectively.
- 6 -
Date Recue/Date Received 2020-09-22
100171 Further, the monoclonal antibody is preferably a chimeric antibody or a
humanized
antibody.
[0018] In some embodiments, the concentration of the anti-HER2 monoclonal
antibody-vc-MMAE is 5-30 mg/ml.
100191 In some embodiments, the non-reducing sugar is 240-260 mmol/L of
mannitol and/or 40
mmol/L-60 mmol/L of sucrose, the amino acid is 8-12 mmol/L of histidine
hydrochloride, and the
solubilizer is 0-0.02% (w/v) of Tween 80.
100201 In some embodiments, wherein the non-reducing sugar is about 260 mmol/L
of
mannitol and about 40 mmol/L of sucrose, the amino acid is about 10 mmol/L of
histidine
hydrochloride, the concentration of the antibody-drug conjugate is about 10
mg/ml, and the
solubilizer is about 0.02% (w/v) of Tween 80.
[0021] In some embodiments, wherein the non-reducing sugar is about 240 mmol/L
of
mannitol and about 60 mmol/L of sucrose, the amino acid is about 10 mmol/L of
histidine
hydrochloride, the concentration of the antibody-drug conjugate is about 10
mg/ml, and the
.. solubilizer is about 0.02% (w/v) of Tween 80.
[0022] Further, the formulation has a pH of 4.5-7, preferably 5.6-6.8, more
preferably 5.6-6.5,
5.6-6.4, 5.6-6.3, 6.1-6.4, or 6.1-6.3.
100231 The pH of the formulation is adjusted with NaOH or hydrochloric acid.
[0024] In some embodiments, the lyophilized pharmaceutical formulation is
obtained by
lyophilization of the above aqueous liquid pharmaceutical formulation.
[0025] Further, before lyophilization, the aqueous liquid pharmaceutical
formulation comprises
about 260 mmol/L of mannitol, about 40 mmol/L of sucrose, about 10 mmol/L of
histidine
hydrochloride, about 0.02% (w/v) of Tween 80, and about 10 mg/ml of anti-HER2
monoclonal
antibody-vc-MMAE, and has a pH of 5.6-6.8.
[0026] Further, before lyophilization, the aqueous liquid pharmaceutical
formulation comprises
about 240 mmol/L of mannitol, about 60 mmol/L of sucrose, about 10 mmol/L of
histidine
hydrochloride, 0.02% of Tween 80, and about 10 mg/ml of anti-HER2 monoclonal
antibody-vc-MMAE, and has a pH of 5.6-6.8.
- 7 -
Date Recue/Date Received 2020-09-22
100271 Further, before lyophilization, the non-reducing sugars comprised in
the aqueous liquid
pharmaceutical formulation are mannitol and sucrose at concentrations of about
47.36 mg/ml and
about 13.69 mg/ml, respectively, and the amino acid is histidine hydrochloride
at a concentration
of about 2.10 mg/ml, and the solubilizer is Tween 80 at a content of about
0.02% (w/v).
100281 Further, before lyophilization, the non-reducing sugars comprised in
the aqueous liquid
pharmaceutical formulation are mannitol and sucrose at concentrations of about
43.72 mg/ml and
about 20.54 mg/ml, respectively, and the amino acid is histidine hydrochloride
at a concentration
of about 2.10 mg/ml, and the solubilizer is Tween 80 at a content of about
0.02% (w/v).
100291 The present invention further provides the use of the above
pharmaceutical formulations
in the manufacture of a medicament for treating a disease caused by abnormal
expression of Her2,
preferably cancer; further preferably Her2 positive cancer; further preferably
breast cancer,
ovarian cancer, gastric cancer, urothelial cancer, gastroesophageal cancer,
oesophageal cancer,
endometrial cancer, lung cancer, or bladder cancer (Reference 3: Human
Epidermal Growth
Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic
Implications, Nida Iqbal
and Naveed Iqbal, Molecular Biology International, Volume 2014, Article ID
852748; and
Reference 4: CN201810998055.4).
[0030] The present invention further provides a method for preparing a
pharmaceutical
formulation for an antibody-drug conjugate, comprising:
(1) preparing the formulation of any one of the above; and
(2) evaluating the stability of the antibody-drug conjugate in the
formulation.
100311 BRIEF DESCRIPTION OF DRAWINGS
[0032] Figure 1 shows SDS-PAGE electrophoresis of the naked antibody after
purification, in
which, 1-2: non-reducing electrophoresis; and 3-4: reducing electrophoresis.
The result in Figure
1 shows that the purity of the monoclonal antibody obtained in the experiment
meets the
requirements of further experiments.
[0033] Figure 2 shows 10% SDS-PAGE electrophoresis of ADC after conjugation,
in which,
Na: non-reducing electrophoresis; Nb: non-reducing electrophoresis after the
antibody is reduced
- 8 -
Date Recue/Date Received 2020-09-22
by TCEP; Ra: reducing electrophoresis of RC48-vc-MMAE; and Rb: reducing
electrophoresis
after the antibody is reduced by TCEP. The result of Figure 2 shows that the
purity of the
obtained ADC after conjugation meets the requirements of further experiments.
EXAMPLES
Example 1 Purification of Antibody
[0034] The murine-derived monoclonal antibody mRC48 and related humanized
antibody
RC48 were obtained based on the methods disclosed in the Example of the patent
application
(CN105008398A or W02015074528A1), wherein RC48 comprised human IgGlx heavy
chain
constant region and heavy chain variable region RC48-VH, and human IgGlx light
chain
constant region and light chain variable region RC48-VL. Each of the above
fragments was
amplified and then subcloned into the expression vector pcDNA3.0,
respectively. The constructed
plasmids were transfected into suspended CHO cells (Invitrogen). The cells
were cultured under
standard conditions. When the nutrients in the medium were exhausted and the
cells no longer
grow, the culture mixture was collected. Then the cells were separated by
centrifugation or
filtration, and the supernatant containing the antibody protein collected and
loaded onto the
Protein A affinity chromatography column for the first purification. The
eluted target protein was
loaded onto a chromatographic column filled with cation packing for the second
purification. The
target protein was collected and then loaded onto the third column for the
third purification in a
target protein penetration mode. The purified protein that has passed the test
on various indicators
was then concentrated by ultrafiltration to obtain a protein with a
concentration of about 20-30
mg/ml, which was the antibody protein stock solution and can be stored at -80
C for a long time.
[0035] Wherein, the CDR sequence of the RC48 antibody is as follows.
Table 4 CDR sequences of RC48 antibody
- 9 -
Date Recue/Date Received 2020-09-22
envy Chan (Vt) Light Chain (VI,)
CDR'. DirVIM OW ID NO. 1) KAMM VGI 14#. VA (SEQ. M
1N1), 4)
CDR2 RVNPDIDIDSYVNQICERD (REV ID Mk 2) WANIRHT (SEQ ID NO. 5)
CDP3 ARNYLEDIIW (SE() ID NO. 3) !TWAT\ T (SEQ ID NO. 6)
Example 2 Conjugation of Antibody to MMAE
[0036] Conjugation of humanized antibody RC48 to drug molecules
100371 Firstly, the stock solutions of TCEP (Tris-2-carboxyethyl-phosphine)
and DTPA
(Diethylene triamine pentacetate acid) were dissolved/diluted in the
conjugation buffer
respectively, and then mixed with the monoclonal antibody in a volume ratio of
1:1 (v:v=1:1), in
which the molar ratio of the final concentration of TCEP to the antibody was
1.9:1, the final
concentration of DTPA was 1 mmol/L, and the reaction was performed with
stirring at 25 C for 2
h. The reductive reaction with TCEP had a good reproducibility, and the
numbers of free thiol
could reach 3.5-4.5 after reduction.
100381 After reduction with TCEP, the antibody may be directly subjected to
subsequent
conjugation. Drugs (vc-MMAE, vc-MMAF, mc-MMAF) were dissolved in DMSO
(dimethyl
sulfoxide) to a concentration of 10 mmol/L. The drugs were added slowly in the
molar ratio of the
drug to thiol of 1.1:1 to the antibody, and the reaction was performed with
stirring at 25 C for 2 h.
The free thiol concentration was detected at 412 nm by DTNB method (close to
zero), the
residual unreacted drugs and free small molecules such as DMSO were removed by
purification,
and the conjugation result was determined by SDS-PAGE electrophoresis, SEC and
HPLC
methods. The conjugation reaction had a good reproducibility, and the open
free thiol can be
conjugated completely with a conjugation degree of 3.5-4.5.
Example 3 Effect of pH on Dissolution and Purity of Recombinant humanized Her-
2
- 10 -
Date Recue/Date Received 2020-09-22
Antibody-MMAE Conjugate (RC48-vc-MMAE)
[0039] Experimental procedure
[0040] 2 g of recombinant humanized anti-Her2 monoclonal antibody-MMAE
conjugate for
injection was ultrafiltered and dialyzed into a buffer containing 0.1 mol/L
citric acid, 0.02 mol/L
trihydroxymethyl aminomethane, 0.02 mol/L sodium dihydrogen phosphate and 0.15
mol/L
sodium chloride in a dialysis ratio of not less than 104 times. The obtained
solution was divided
into 13 parts equally, and each part was concentrated to a protein
concentration of 10 mg/ml by a
centrifugal ultrafiltration tube with a pore size of 30 kDa, and then the pH
was adjusted to 4.2, 4.6,
5.0, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, or 7.4 with hydrochloric
acid or sodium hydroxide
solution. The clarity was observed and the change in the concentration was
detected (the results
are as shown in Table 5). The samples were respectively filtered into sterile
20 ml penicillin
bottles with a sterile syringe filter with a pore size of the membrane of 0.22
micron in the super
clean bench, with 3 bottles of each pH value. Each bottle was sealed with a
sterile rubber stopper
and tied with an aluminum cap, and stored at 25 C. Samples were taken with a
sterile syringe at
0 hour, 1 day, 3 days, and 7 days for SEC-El:PLC analysis and the results are
as shown in Table 6.
[0041] Studies have found that the pH of the protein under experimental
conditions has a great
impact on the dissolution of the protein. The protein precipitated below pH
5.4 and dissolved well
above pH 5.6; and the protein aggregates did not increase after 3 days and
slightly increased after
7 days when stored below pH 6.8, increased with time above pH 7.0, and the
higher the pH, the
more the aggregates (see Table 5 and Table 6).
Table 5 Clarity and protein concentration
0 hour 1 day 3 days 7 days
pH Concentrati Concentrati Concentrati
Concentration
Clarity on Clarity on Clarity on Clarity
'm /ml
(mg/ml) (mg/ml) (mg/ml)
Massive Massive Massive
Massive
4.2 6.34 Precipita 5.67 Precipit 5.21 Precipit 4.40
Precipitates
tes ates ates
Massive Massive Massive
Massive
4.6 6.63 Precipita 5.53 Precipit 5.46 Precipit 4.82
Precipitates
tes ates ates
Sli ht Slight Slight Slight
5.0 8.82 Precipita 8.17 Precipit 7.98 Precipit
7.64
Precipitates
tes ates ates
5.4 Slight 8.99 Slight 8.78 Slight 8.45 Slight
8.10
- 11 -
Date Recue/Date Received 2020-09-22
Precipitates Precipita Precipit Precipit
tes ates ates
5.6 Clear 9.99 Clear 10.01 Clear 10.00 Clear 9.96
5.8 Clear 10.03 Clear 10.00 Clear 9.98 Clear 9.97
6.0 Clear 9.97 Clear 9.99 Clear 10.01 Clear
10.00
6.2 Clear 10.00 Clear 9.98 Clear 9.97 Clear 9.98
6.4 Clear 9.95 Clear 9.97 Clear 9.98 Clear
10.00
6.6 Clear 9.97 Clear 9.96 Clear 10.02 Clear 9.95
6.8 Clear 10.05 Clear 10.01 Clear 9.96 Clear 9.97
7.0 Clear 10.02 Clear 10.01 Clear 10.00 Clear
10.03
7.4 Clear 10.00 Clear 10.03 Clear 9.99 Clear 9.97
Table 6 Purity
H
0 hour (A) 1 day (A) 3 days (A) 7 days
(A)
p .
PurrtyAggregateDegradationPurityAggregateDegradationPurityAggregateDegradationP
urityAggregateDegradation
5.6 99.6 0.4 0 99.5 0.5 0 99.2 0.8 0 98.5 1.5
0
5.8 99.5 0.5 0 99.7 0.3 0 99.1 0.9 0 98.3 1.7
0
6.0 99.4 0.6 0 99.5 0.5 0 99.1 0.9 0 98.4 1.6
0
6.2 99.6 0.4 0 99.3 0.7 0 99.0 1.0 0 98.5 1.5
0
6.4 99.5 0.5 0 99.3 0.7 0 99.2 0.8 0 98.3 1.7
0
6.6 99.5 0.5 0 99.4 0.6 0 99.2 0.8 0 98.3 1.7
0
6.8 99.6 0.4 0 99.5 0.5 0 99.0 1.0 0 98.2 1.8
0
7.0 99.5 0.5 0 99.1 0.9 0 98.6 1.4 0 97.1 2.9
0
7.4 99.6 0.4 0 98.3 1.7 0 97.2 2.8 0 96.4 3.6
0
Example 4 Screening of Adjuvants
100421 Through the analysis of a large amount of information and the screening
through
experiments in the early stage, sucrose, mannitol, glycerol, histidine,
arginine, polysorbate 80 (i.e.
Tween 80) and the like were preliminarily identified as candidate adjuvants
for further screening,
and the following tests were further carried out.
Table 7 Screening of adjuvants for RC48-vc-MMAE injection
Histidine
Formula Arginine Sucrose Mannitol
Glycerol Tween 80 Protein LT
Hydrochloride
Number (mmol/Lol/L) (mmol/Lol/L) (mmol/Lol/L) (%) (%) (mg/ml) 11¶
(mmol/Lol/L)
Al 10 35 0 240 0 0 10
6.3
A 2 10 35 0 240 0 0.02 10
6.3
A 3 10 0 60 240 0 0 10
6.3
A 4 10 0 60 240 0 0.02 10
6.3
A 5 10 0 0 200 1.0 0 10
6.3
A 6 10 0 0 200 1.0 0.02 10
6.3
A 7 10 0 0 300 0 0 10
6.3
Date Recue/Date Received 2020-09-22
A8 10 0 0 300 0 0.02 10
6.3
Table 8 Clarity of RC48-vc-MMAE injection
Formula Number 0 hour 1 day 3 days 7 days
Al ++ ++ ++ ++
A2 - - - -
A3 H-F H-F H-F H-F
- A 4 - - -
-
A5
- - -
-
A6
- - -
A7 H-F H-F H-F H-F
- A 8 - - -
100431 Note: "-" indicates that the number of white dots (visible
precipitates) is less than 3, "+"
indicates that the number of white dots (visible precipitates) is between 3-5,
and "++" indicates
that the number of white dots (visible precipitates) is more than 5.
Table 9 Purity of RC48-vc-MMAE injection
Formula
0 hour(%) 1 day (%) 3 days (%) 7 days (%)
Number
Al 99.5 99.2 99.0 98.2
A2 99.6 99.1 98.8 98.3
A3 99.5 99.6 99.5 99.5
A4 99.7 99.6 99.6 99.6
A5 99.4 99.1 98.7 98.2
A6 99.5 98.9 98.6 98.3
A7 99.6 99.0 98.6 98.0
A8 99.5 98.9 98.3 98.2
[0044] It can be seen from the above results that the addition of arginine had
no obvious effect
on eliminating the visible precipitates of the protein. While the addition of
sucrose, glycerol and
polysorbate 80 can all improve the condition of the protein. Therefore, it was
determined that an
.. appropriate amount of sucrose may be added to the formulation to protect
the protein, and
glycerol and polysorbate 80 may be added to promote the dissolution of the
protein.
- 13 -
Date Recue/Date Received 2020-09-22
Example 5 Vacuum freeze drying
[0045] The protein stock solution was taken out from the -80 C refrigerator,
thawed, diluted
accurately with "lx formulation buffer" to a protein concentration of 10
mg/ml, and subpackaged
into a sterile, pyrogen-free standard 20 ml lyophilized penicillin bottle, 6
ml per bottle, and then
subjected to freeze drying in vacuum.
[0046] Freeze drying conditions
[0047] Pre-freezing: -45 C for 5 hours;
100481 Primary drying: -26 C for 40 hours, at vacuum degree of 10-15 Pa; and
100491 Secondary drying: 25 C for 10 hours, at vacuum degree of 10-15 Pa.
[0050] After lyophilization, the bottle was sealed with a rubber stopper in a
vacuum state, taken
out of the lyophilizer and put on an aluminum cap.
Example 6: Screening Formulas
100511 Based on the formulas designed in Table 10, the appearance and shaping
stability of the
lyophilized powders of the formulations were examined. After lyophilization,
the samples were
stored at 4 C and 37 C. The appearance of the samples was observed on days
0, 1, 3, and 7,
respectively, and the corresponding formulas with better appearance and shape
were screened out.
The results are shown in Table 11.
Table 10 List of buffer formulas for RC48-vc-IVIMAE injection
Histidine
Formula Sucrose Mannitol Glycerol Tween 80 Protein H
Hydrochloride
Number (mmol/Lol/L) (mmol/Lol/L) (%) (%) (mg/ml) P
(mmol/Lol/L)
B1 10 40 260 0 0 10
6.3
B2 10 40 260 0 0.02 10
6.3
B3 10 60 240 0 0 10
6.3
B4 10 60 240 0 0.02 10
6.3
B5 10 100 200 0 0 10
6.3
B6 10 100 200 0 0.02 10
6.3
B7 10 40 240 0.2 0 10
6.3
B 8 10 40 240 0.2 0.02 10
6.3
B9 10 60 190 0.5 0 10
6.3
B 10 10 60 190 0.5 0.02 10
6.3
- 14 -
Date Recue/Date Received 2020-09-22
B 11 10 100 100 1.0 0 10
6.3
B 12 10 100 100 1.0 0.02 10
6.3
Table 11 Appearance observation of lyophilized powders
Appearance
Formula
4 C 37 C
Number
0 hour 1 day 3 days 7 days 0 hour 1 day 3 days 7 days
B1 ++ ++ ++ ++ ++ ++ ++ ++
B2 ++ ++ ++ ++ ++ ++ ++ ++
B3 ++ ++ ++ ++ ++ ++ ++ ++
B4 ++ ++ ++ ++ ++ ++ ++ ++
B5 ++ ++ ++ ++ ++ ++ ++ ++
B6 ++ ++ ++ ++ ++ ++ ++ ++
B7 ++ ++ ++ ++ ++
B8 ++ ++ ++ ++ ++
B9 ++ ++ ++ ++ ++
B 10 ++ ++ ++ ++ ++
B 11 ++ ++ ++ ++ ++
B 12 ++ ++ ++ ++ ++
[0052] Note: 1) "- -" indicates that the volume of product is reduced to less
than half of its
volume before lyophilization; "-" indicates that the volume of product is
reduced to more than
.. half of its volume before lyophilization; "+" indicates that only the edge
has slight shrinkage, and
the volume of product is basically the same as that of before lyophilization;
and "++" indicates
that there is no volume change at all, and the volume of the product is the
same as before
lyophilization. 2) Qualified standards for the appearance of lyophilized
powders are: uniform
color, even and dense pores, and the volume and shape before and after
lyophilization remain
.. basically unchanged, showing a block or sponge-like structure. It can be
seen from Table 11 that
the formulation containing glycerol in the formula showed slight shrinkage
after being placed at
37 C for one day, and showed obvious shrinkage and collapse after being
placed at 37 C for
seven days. Therefore, glycerol was excluded as an adjuvant for the ADC
formulation.
Example 7 Determination of Formula and Stability Test of Lyophilized Powders
[0053] The formulas B7-B12 were eliminated after the appearance inspection for
lyophilized
- 15 -
Date Recue/Date Received 2020-09-22
powders. The adjuvants of formulas B1-B6 were further screened through the
inspection for
moisture content, visible precipitates, insoluble microparticles, and the
stability.
100541 The lyophilized powders of each formula were stored at 37 C, 25 C and
4 C, and then
sampling at different times and subjected to assays of SDS-PAGE, reverse phase
HPLC, ligand
binding assay, biological activity, moisture content, appearance, pH value,
visible precipitates,
insoluble microparticles and the like.
Table 12 Appearance observation of lyophilized powders
Formula
B1 B2 B3 B4 B5 B6
Number
Appearance ++ ++ ++ ++ ++ ++
[0055] Note: "- -" indicates that the volume of product is reduced to less
than half of its volume
before lyophilization; "-" indicates that the volume of product is reduced to
more than half of its
volume before lyophilization; "+" indicates that only the edge has slight
shrinkage, and the
volume is basically the same as before lyophilization; and "++" indicates that
there is no
shrinkage at all, and the volume of the product is the same as before
lyophilization.
[0056] It can be seen from Table 12 that the appearance of the lyophilized
powders of formulas
B1-B6 all meet the standard requirements.
100571 Three samples were picked from each formula and tested for the moisture
content
according to the prescribed method. The average value of the moisture content
was calculated and
the results are shown in Table 12.
Table 12 Moisture contents of lyophilized powders
Formula Number B1 B2 B3 B4 B5 B6
Moisture Content
0.658 0.586 0.557 0.606 0.571 0.560
(A)
[0058] The moisture contents of formulas B 1, B2, B3, B4, B5, and B6 were all
less than 3%,
which was qualified.
[0059] Five samples per formula were randomly chosen, and the visible
precipitates were
inspected after the sample was redissolved according to the prescribed method.
Then, three of the
five samples per formula were sampled and the insoluble microparticles were
measured
according to the prescribed method. The results are shown in Table 13.
- 16 -
Date Recue/Date Received 2020-09-22
Table 13 Visible precipitates and insoluble microparticles after redissolution
of lyophilized
powders
Visible precipitate Number of Insoluble
Formula Number
(Average Number) Microparticle (>10 [tm)
B1 4.3 7542
B2 0.6 642
B3 5.0 6792
B4 0.5 650
B 5 7.7 9168
B6 1.2 926
100601 It can be seen from the results of visible precipitates and insoluble
microparticle that the
formulas Bl, B3, and B5 did not meet the requirements and were therefore
excluded.
Table 14 Results of stability after storage at 37 C for 1 month
H1C-HPLC
Binding Cell Moisture Number Insoluble
Insoluble
Formula SEC-HP Average Activity Viability Content
Appearaof Visible pH Microparticle Microparticle
Number LC (%) Conjugation nce
Rate
(IC50)(pM) (IC50)(pM) (%) precipitate
(>10 um) (>25 um)
132 99.02 3.98 15.23 65.2 0.889 ++ 1 6.30 669
9.0
134 99.18 3.99 12.59 57.6 0.896 ++ 0 6.30 645
6.0
B6 99.12 3.96 14.77 57.8 0.902 ++ 6 6.30 6418
692.0
Table 15 Results of stability after storage at 25 C for 3 months
HIC-HPLC Number
Binding Cell Moisture
Insoluble Insoluble
Formula SEC-HP Average Appea
of Visible
Activity Viability Content pH
Microparticle Microparticle
Number LC (%) Conjugation rance
precipitate
(IC50)(pM) (IC50)(pM) (%) (>10 um) (>25 um)
Rate s
B2 99.12 4.03 13.27 55.2 0.789 ++ 0 6.30
300 12.0
134 99.25 4.05 12.68 56.1 0.796 ++ 0 6.30
315 6.0
B6 99.34 4.05 12.91 55.6 0.806 ++ 6 6.30
6209 646.0
Table 16 Results of stability after storage at 4 C for 6 months
- 17 -
Date Recue/Date Received 2020-09-22
H1C-HPLC
Binding Cell Moisture Number
Insoluble Insoluble
Formula SEC-HP Average Appea
Activity Viability Content of Visible
pH Microparticle Microparticle
Number LC (%) Conjugating rance
(IC50)(pM) (IC50)(pM) (%) precipitate (>10
um) (>25 um)
Rate
B2 99.45 4.01 13.23 55.4 0.560 ++ 0 6.30 618
6.0
B4 99.48 3.99 12.19 57.1 0.579 ++ 0 6.30 672
0.0
B6 99.21 3.95 13.30 56.5 0.589 ++ 4 6.30
6120 610.0
Note: appearance standard: "- 2 indicates that the volume of product is
reduced to less than half
of its volume before lyophilization; "2 indicates that the volume of product
is reduced to more
than half of its volume before lyophilization; "+" indicates that only the
edge has slight shrinkage,
and the volume of the product is basically the same as before lyophilization;
and "++" indicates
that there is no shrinkage at all, and the volume of the product is the same
as before
lyophilization.
[0061] It can be seen from the above results that products of formulas B2 and
B4 have better
stability at different temperatures (4 C, 25 C, 37 C), while product of
formula B6 has many
insoluble particles and was therefore excluded. It can be seen from the above
tests that
lyophilized powders of formulas B2 and B4 have an excellent performance in
terms of
appearance, moisture content, visible precipitates and insoluble
microparticles after redissolution
of lyophilized powder, and stability.
[0062] Based on the above experimental evidence, it can be seen that the
selection of specific
adjuvants in a class of substances such as non-reducing sugars, amino acids,
and solubilizer has
an unpredictable effect on the final formulation. For the Her2 monoclonal
antibody-drug
conjugate of the present invention, a large number of experiments are needed
to test various
properties in order to finally obtain a good combination of ingredients. For
example, the addition
of arginine has no obvious effect on eliminating the visible precipitates of
the protein, and the
addition of sucrose, glycerol and polysorbate 80 can all reduced the
aggregation of the protein.
However, the addition of glycerol will make the lyophilized product prone to
show obvious
shrinkage and collapse in the appearance of the reconstituted aqueous solution
after reconstitution.
In addition, too high concentration of sucrose or too low concentration of
mannose will lead to an
increase in insoluble matter after reconstruction. These results were
difficult for those skilled in
- 18 -
Date Recue/Date Received 2020-09-22
the art to predict before conducting relevant tests. In addition, since ADC
formulation involves
the combined use of multiple adjuvants, long-term stability tests and other
factors, this makes it
quite difficult to develop an ADC formulation. Through a large number of
experiments, we have
determined the Her2 ADC formulation combination with excellent performance in
all aspects.
The anti-Her2 monoclonal antibody-MMAE conjugate can dissolve well before and
after
lyophilization, and both the insoluble microparticles and the visible
precipitates meet the
standards for human injection; at the same time, the conjugate can be kept
stable for a long time
during lyophilization and storage, especially, it still maintains good
stability after long-term
storage at a high temperature of 25 C or 37 C. Furthermore, the ADC
formulation is not easily
to polymerize or be degraded after reconstitution, and maintains good
biological activity.
- 19 -
Date Recue/Date Received 2020-09-22
